Pfizer & Valneva Report Phase 3 Results for Lyme Disease Vaccine: A Step Closer, But Not Perfect

Pfizer & Valneva Report Phase 3 Results for Lyme Disease Vaccine: A Step Closer, But Not Perfect

By, Admin 25 March 2026

A long-awaited Lyme disease vaccine is moving closer to reality. Pfizer Inc. and Valneva SE have announced topline Phase 3 results for their investigational vaccine PF-07307405 (formerly VLA15). The headline:

More than 70% efficacy—but with a statistical caveat.

The VALOR Trial: What Was Studied

The Phase 3 VALOR trial evaluated the vaccine across:

  • United States
  • Canada
  • Europe

Trial Design:

  • Randomized, placebo-controlled
  • Observer-blinded
  • Participants aged 5+
  • 4-dose regimen:
    • Months 0, 2, 5–9
    • Booster before the next Lyme season

Efficacy Results: Strong, But Mixed

Key Findings (Season 2)

  • 73.2% efficacy (28 days after dose 4)
  • 74.8% efficacy (1 day after dose 4)

Both results show meaningful protection against Lyme Disease.

The Catch: Primary Endpoint Missed

Here’s where things get nuanced. The trial had a strict statistical requirement:

  • Lower bound of 95% confidence interval >20

What happened:

  • First analysis → Did NOT meet this threshold
  • Second analysis → DID meet the threshold

Why? Fewer Lyme cases occurred than expected during the trial. This reduced statistical power.

What Pfizer Is Saying?

Annaliesa Anderson emphasized:

  • Lyme disease has serious long-term consequences
  • No vaccine currently exists
  • 70%+ efficacy is “highly encouraging”

Despite the technical miss, Pfizer plans to -move forward with regulatory submissions.

Valneva’s Perspective

Thomas Lingelbach called the results: A step closer to delivering a much-needed vaccine The partnership, formed in 2020, gives Pfizer:

  • Exclusive manufacturing rights
  • Global commercialization control

Why This Vaccine Matters?

There is currently no approved human vaccine for Lyme disease. And the burden is growing.

Disease Impact:

  • ~476,000 cases annually in the US
  • ~132,000 cases reported in Europe

Transmission:

  • Caused by Borrelia bacteria
  • Spread via infected tick bites

Symptoms:

  • Early: rash, fatigue, fever
  • Late: arthritis, heart issues, neurological damage

Left untreated, it can become chronic and debilitating.

How the Vaccine Works?

PF-07307405 uses a 6-valent OspA-based approach.

Mechanism:

  • Targets outer surface protein A (OspA) of bacteria
  • Generates antibodies in the human body
  • When a tick feeds:
    • Antibodies enter the tick
    • Block bacteria transmission

This is a unique vector-blocking strategy, stopping infection before it reaches the human host.

The Bigger Picture: A First-in-Class Opportunity

This vaccine is:

  • The most advanced Lyme vaccine candidate globally
  • Backed by two completed Phase 3 trials

If approved, it would:

  • Be the first Lyme disease vaccine for humans
  • Address a growing public health need
  • Open a new preventive market

Final Take

This is not a clean, textbook success. But it’s far from a failure.

What we have:

  • Strong efficacy (~70%)
  • No existing competition
  • Clear unmet need

What’s uncertain:

  • Regulatory interpretation of mixed statistical results

Pfizer is betting that clinical relevance outweighs statistical technicalities. If regulators agree, this could become one of the most important vaccine launches in infectious disease prevention in years.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!